Stonepine Capital Management’s ADMA Biologics ADMA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $13.7M | Sell |
750,000
-60,000
| -7% | -$1.09M | 13.4% | 1 |
|
|
2025
Q1 | $24.3K | Sell |
810,000
-431,032
| -35% | -$12.9K | 0.02% | 62 |
|
|
2024
Q4 | $21.3M | Sell |
1,241,032
-628,968
| -34% | -$10.8M | 17.18% | 1 |
|
|
2024
Q3 | $37.4M | Hold |
1,870,000
| – | – | 23.62% | 1 |
|
|
2024
Q2 | $20.9M | Sell |
1,870,000
-1,556,882
| -45% | -$17.4M | 19.07% | 1 |
|
|
2024
Q1 | $22.6M | Sell |
3,426,882
-5,795,735
| -63% | -$38.3M | 17.94% | 2 |
|
|
2023
Q4 | $41.7M | Buy |
9,222,617
+118,342
| +1% | +$535K | 18.03% | 2 |
|
|
2023
Q3 | $32.6M | Buy |
9,104,275
+310,954
| +4% | +$1.11M | 10.83% | 4 |
|
|
2023
Q2 | $32.4M | Buy |
8,793,321
+1,131,631
| +15% | +$4.18M | 11.7% | 3 |
|
|
2023
Q1 | $25.4M | Buy |
7,661,690
+721,690
| +10% | +$2.39M | 8.51% | 4 |
|
|
2022
Q4 | $26.9M | Buy |
6,940,000
+1,940,000
| +39% | +$7.53M | 11.33% | 4 |
|
|
2022
Q3 | $12.2M | Sell |
5,000,000
-2,000,000
| -29% | -$4.86M | 5.46% | 6 |
|
|
2022
Q2 | $13.9M | Sell |
7,000,000
-131,808
| -2% | -$261K | 6.45% | 4 |
|
|
2022
Q1 | $13.1M | Sell |
7,131,808
-2,779,769
| -28% | -$5.09M | 5.41% | 6 |
|
|
2021
Q4 | $14M | Buy |
+9,911,577
| New | +$14M | 6.41% | 4 |
|
|
2018
Q3 | – | Sell |
-831,731
| Closed | -$3.75M | – | 33 |
|
|
2018
Q2 | $3.75M | Buy |
+831,731
| New | +$3.75M | 2.28% | 15 |
|
|
2018
Q1 | – | Sell |
-67,647
| Closed | -$217K | – | 31 |
|
|
2017
Q4 | $217K | Buy |
+67,647
| New | +$217K | 0.13% | 26 |
|